[A17-13] Tenofovir alafenamide (chronic hepatitis B) – Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2017
Project no.:
A17-13
Commission:
Commission awarded on 30.03.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-09-21 A G-BA decision was published.